Government-Owned Inventions; Availability for Licensing and/or Co-Development, 81150-81151 [2016-27613]
Download as PDF
<![CDATA[
81150
Federal Register / Vol. 81, No. 222 / Thursday, November 17, 2016 / Notices
Emphasis Panel; NIAID Resource-Related
Research Projects (R24).
Date: December 12, 2016.
Time: 2:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Room 3E73, Rockville, MD
20892 (Telephone Conference Call).
Contact Person: Audrey O. Lau, Ph.D.,
Scientific Review Officer, Scientific Review
Program, DEA/NIAID/NIH/DHHS, 5601
Fishers Lane, MSC–9823, Rockville, MD
20852, 240–669–2081, audrey.lau@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: November 14, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–27675 Filed 11–16–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; Phase II
In-person Interview: NIDA Avant-Garde
Award Program for HIV/AIDS Research
(DP1).
Date: December 12, 2016.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Courtyard by Marriott, 5520
Wisconsin Avenue, Chevy Chase, MD 20815.
Contact Person: Hiromi Ono, Ph.D.,
Scientific Review Officer, Office of
Extramural Affairs, National Institute on
Drug Abuse, National Institutes of Health,
DHHS, 6001 Executive Boulevard, Room
4238, MSC 9550, Bethesda, MD 20892, (301)
827–5820, hiromi.ono@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
VerDate Sep<11>2014
21:24 Nov 16, 2016
Jkt 241001
Laboratory and Diagnostic Tools to Advance
Microbiome-Brain Research (R41/R42/R43/
R44).
Date: December 13, 2016.
Time: 10:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Garden Inn Bethesda, 7301
Waverly Street, Bethesda, MD 20814.
Contact Person: Gerald L. McLaughlin,
Ph.D., Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, NIH, DHHS, 6001
Executive Blvd., Room 4238, MSC 9550,
Bethesda, MD 20892–9550, 301–827–5819,
gm145a@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; Multisite Clinical Trials SEP II.
Date: December 14, 2016.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Susan O. McGuire, Ph.D.,
Scientific Review Officer, Office of
Extramural Affairs, National Institute on
Drug Abuse, National Institutes of Health,
DHHS, 6001 Executive Blvd., Room 4245,
Rockville, MD 20852, (301) 827–5817,
mcguireso@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: November 14, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–27677 Filed 11–16–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing and/or CoDevelopment
AGENCY:
National Institutes of Health.
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing and/or co-development in the
U.S. to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing and/or co-development.
ADDRESSES: Invention Development and
Marketing Unit, Technology Transfer
SUMMARY:
PO 00000
Frm 00098
Fmt 4703
Sfmt 4703
Center, National Cancer Institute, 9609
Medical Center Drive, Mail Stop 9702,
Rockville, MD 20850–9702.
FOR FURTHER INFORMATION CONTACT:
Information on licensing and codevelopment research collaborations,
and copies of the U.S. patent
applications listed below may be
obtained by contacting: Attn. Invention
Development and Marketing Unit,
Technology Transfer Center, National
Cancer Institute, 9609 Medical Center
Drive, Mail Stop 9702, Rockville, MD,
20850–9702, Tel. 240–276–5515 or
email ncitechtransfer@mail.nih.gov. A
signed Confidential Disclosure
Agreement may be required to receive
copies of the patent applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Title of invention: Gene Signature
Predictive of Hepatocellular Carcinoma
Response to Transcatheter Arterial
Chemoembolization (TACE).
Keywords: Diagnostic, Biomarker,
Prognostic, Hepatocellular Carcinoma,
Patient Stratification, TACE, HCC.
Description of Technology:
Hepatocellular Carcinoma (HCC) is one
of the most common cancers worldwide
with largely unfavorable outcomes due
to a lack of effective treatment options
for patients in the later state of disease.
The gold standard of care for HCC
patients with intermediate to locally
advanced tumors is transcatheter
arterial chemoembolization (TACE), a
procedure whereby the tumor is targeted
both with local chemotherapy and
restriction of local blood supply. TACE
procedures are often not effective,
however, and a need exists to identify
patients that will respond to TACE.
Scientists in NCI’s Laboratory of
Human Carcinogenesis have identified a
14-gene signature that is predictive of
response to TACE. The ‘‘TACE
Navigator Gene Signature Assay,’’ based
on a Nanostring Technologies platform,
is useful in identifying those HCC
patients, prior to treatment, who will
respond to and have the greatest
survival benefit following TACE. The
signature can also identify patients who
need additional/alternative therapeutic
modalities.
This invention is owned by an agency
of the U.S. Government and is available
for licensing and/or co-development in
the U.S., in accordance with 35 U.S.C.
209 and 37 CFR part 404, to achieve
expeditious commercialization of
results of federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing and/or co-development.
E:\FR\FM\17NON1.SGM
17NON1
Federal Register / Vol. 81, No. 222 / Thursday, November 17, 2016 / Notices
Potential Commercial Applications:
• Prognostic test for HCC patient
response to TACE procedure
• Companion diagnostic for TACE
procedure
Value Proposition:
• First in class prognostic diagnostic for
frontline therapy in highly prevalent
HCC
Development Stage: Basic (Target ID).
Inventor(s): Xin Wei Wang, Ph.D. and
Valerie Miller, Ph.D. (NCI).
Intellectual Property:
HHS Reference No. E–101–2016
U.S. Provisional Application 62/292,789
(HHS Reference No. E–101–2016/0–
US–01) filed February 8, 2016 entitled
‘‘Gene Signature Predictive of
Hepatocellular Carcinoma Response
to Transcatheter Arterial
Chemoembolization (TACE)’’
Related Technologies: NIH Reference
No. E–024–2009 entitled ‘‘Gene
Signature for Predicting Solid Tumors
Patient Response’’.
Collaboration Opportunity:
Researchers at the NCI seek licensing
and/or co-development research
collaborations for the commercialization
of a companion diagnostic for HCC
patients undergoing TACE procedures.
Contact Information: Requests for
copies of the patent application or
inquiries about licensing, research
collaborations, and co-development
opportunities should be sent to John D.
Hewes, Ph.D., email: john.hewes@
nih.gov.
Dated: November 8, 2016.
John D. Hewes,
Technology Transfer Specialist, Technology
Transfer Center, National Cancer Institute.
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Rapid Assessment of Zika
Virus (ZIKV) Complications (R21).
Date: December 9, 2016.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Raymond R. Schleef,
Ph.D., Senior Scientific Review Officer,
Scientific Review Program, Division of
Extramural Activities, Room 3E61, National
Institutes of Health/NIAID, 5601 Fishers
Lane, MSC 9823, Bethesda, MD 20892–9823,
(240) 669–5019, schleefrr@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: November 14, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–27674 Filed 11–16–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF THE INTERIOR
Fish and Wildlife Service
[FWS–R1–ES–2016–N185;
FXES11120100000–167–FF01E00000]
[FR Doc. 2016–27613 Filed 11–16–16; 8:45 am]
Final Habitat Conservation Plan and
Supplemental Final Environmental
Impact Statement; Na Pua Makani
Wind Energy Project, Oahu, Hawaii
BILLING CODE 4140–01–P
AGENCY:
Fish and Wildlife Service,
Interior.
ACTION: Notice of availability; notice of
permit application; request for
comments.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
asabaliauskas on DSK3SPTVN1PROD with NOTICES
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
VerDate Sep<11>2014
21:24 Nov 16, 2016
We, the U.S. Fish and
Wildlife Service (Service), received an
incidental take permit application from
Na Pua Makani Power Partners, LLC,
pursuant to the Endangered Species Act
of 1973, as amended (ESA). The
requested permit would authorize the
take of one threatened and six
endangered species caused by covered
activities associated with a wind energy
generation project on the island of
Oahu, Hawaii. The permit application
included the proposed Na Pua Makani
Wind Energy Project Habitat
Conservation Plan (HCP), which
described the activities that may result
in the incidental taking of listed species,
and the measures the applicant will take
SUMMARY:
Jkt 241001
PO 00000
Frm 00099
Fmt 4703
Sfmt 4703
81151
to minimize, mitigate, and monitor for
adverse impacts to the covered species.
The applicant modified the proposed
action in the HCP in response to public
comments and the modified HCP is
available for public review pursuant to
this notice. The Service also announces
the availability of a Supplemental Final
Environmental Impact Statement (SEIS)
addressing the modified proposed
action in accordance with the
requirements of the National
Environmental Policy Act of 1969
(NEPA). If issued, the ITP would
authorize incidental take of the covered
species that may occur as a result of the
construction and operation of the Na
Pua Makani Wind Energy Project
(Project) over a 21-year period. We are
making the permit application package,
including the modified HCP and SEIS,
available for public review and
comment.
DATES: To ensure consideration, written
comments must be received from
interested parties no later than
December 19, 2016.
The Service’s decision on issuance of
an ITP will occur no sooner than 30
days after the publication of the U.S.
Environmental Protection Agency’s
notice of the SEIS in the Federal
Register and will be documented in a
Record of Decision (ROD). (For
information about the EPA notice, see
The Environmental Protection Agency’s
Role in the EIS Process under
SUPPLEMENTARY INFORMATION.)
ADDRESSES: To request further
information or submit written
comments, please use one of the
following methods, and note that your
information request or comments are in
reference to the Na Pua Makani Wind
Energy Project HCP.
• Internet: Documents may be viewed
and downloaded on the Internet at
https://www.fws.gov/pacificislands/.
• Email: NaPuaMakanihcp@fws.gov.
• U.S. Mail: You may obtain a
compact disk with electronic copies of
these documents by writing to Mary
Abrams, Field Supervisor; U.S. Fish and
Wildlife Service; Pacific Islands Fish
and Wildlife Office; 300 Ala Moana
Boulevard, Room 3–122; Honolulu, HI
96850.
• Telephone: Call 808–792–9400
during regular business hours.
FOR FURTHER INFORMATION CONTACT: Ms.
Jodi Charrier or Mr. Aaron Nadig, U.S.
Fish and Wildlife Service (see
ADDRESSES); by telephone 808–792–
9400; or by email at NaPuaMakanihcp@
fws.gov. If you use a
telecommunications device for the deaf,
please call the Federal Relay Service at
800–877–8339.
E:\FR\FM\17NON1.SGM
17NON1
]]>Agencies
[Federal Register Volume 81, Number 222 (Thursday, November 17, 2016)]
[Notices]
[Pages 81150-81151]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-27613]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing and/or
Co-Development
AGENCY: National Institutes of Health. HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing and/or co-development in the
U.S. to achieve expeditious commercialization of results of federally-
funded research and development. Foreign patent applications are filed
on selected inventions to extend market coverage for companies and may
also be available for licensing and/or co-development.
ADDRESSES: Invention Development and Marketing Unit, Technology
Transfer Center, National Cancer Institute, 9609 Medical Center Drive,
Mail Stop 9702, Rockville, MD 20850-9702.
FOR FURTHER INFORMATION CONTACT: Information on licensing and co-
development research collaborations, and copies of the U.S. patent
applications listed below may be obtained by contacting: Attn.
Invention Development and Marketing Unit, Technology Transfer Center,
National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702,
Rockville, MD, 20850-9702, Tel. 240-276-5515 or email
ncitechtransfer@mail.nih.gov. A signed Confidential Disclosure
Agreement may be required to receive copies of the patent applications.
SUPPLEMENTARY INFORMATION: Technology description follows.
Title of invention: Gene Signature Predictive of Hepatocellular
Carcinoma Response to Transcatheter Arterial Chemoembolization (TACE).
Keywords: Diagnostic, Biomarker, Prognostic, Hepatocellular
Carcinoma, Patient Stratification, TACE, HCC.
Description of Technology: Hepatocellular Carcinoma (HCC) is one of
the most common cancers worldwide with largely unfavorable outcomes due
to a lack of effective treatment options for patients in the later
state of disease. The gold standard of care for HCC patients with
intermediate to locally advanced tumors is transcatheter arterial
chemoembolization (TACE), a procedure whereby the tumor is targeted
both with local chemotherapy and restriction of local blood supply.
TACE procedures are often not effective, however, and a need exists to
identify patients that will respond to TACE.
Scientists in NCI's Laboratory of Human Carcinogenesis have
identified a 14-gene signature that is predictive of response to TACE.
The ``TACE Navigator Gene Signature Assay,'' based on a Nanostring
Technologies platform, is useful in identifying those HCC patients,
prior to treatment, who will respond to and have the greatest survival
benefit following TACE. The signature can also identify patients who
need additional/alternative therapeutic modalities.
This invention is owned by an agency of the U.S. Government and is
available for licensing and/or co-development in the U.S., in
accordance with 35 U.S.C. 209 and 37 CFR part 404, to achieve
expeditious commercialization of results of federally-funded research
and development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing and/or co-development.
[[Page 81151]]
Potential Commercial Applications:
Prognostic test for HCC patient response to TACE procedure
Companion diagnostic for TACE procedure
Value Proposition:
First in class prognostic diagnostic for frontline therapy in
highly prevalent HCC
Development Stage: Basic (Target ID).
Inventor(s): Xin Wei Wang, Ph.D. and Valerie Miller, Ph.D. (NCI).
Intellectual Property:
HHS Reference No. E-101-2016
U.S. Provisional Application 62/292,789 (HHS Reference No. E-101-2016/
0-US-01) filed February 8, 2016 entitled ``Gene Signature Predictive of
Hepatocellular Carcinoma Response to Transcatheter Arterial
Chemoembolization (TACE)''
Related Technologies: NIH Reference No. E-024-2009 entitled ``Gene
Signature for Predicting Solid Tumors Patient Response''.
Collaboration Opportunity: Researchers at the NCI seek licensing
and/or co-development research collaborations for the commercialization
of a companion diagnostic for HCC patients undergoing TACE procedures.
Contact Information: Requests for copies of the patent application
or inquiries about licensing, research collaborations, and co-
development opportunities should be sent to John D. Hewes, Ph.D.,
email: john.hewes@nih.gov.
Dated: November 8, 2016.
John D. Hewes,
Technology Transfer Specialist, Technology Transfer Center, National
Cancer Institute.
[FR Doc. 2016-27613 Filed 11-16-16; 8:45 am]
BILLING CODE 4140-01-P
